Intelligent Bio Solutions announced successful recertification to ISO 13485:2016, a critical quality management standard now adopted by the FDA. This regulatory alignment significantly strengthens the company's position for pursuing FDA clearance for its drug screening system, leading to a substantial surge in its stock price.
Intelligent Bio Solutions (INBS) announced its Intelligent Fingerprinting Drug Screening business secured recertification to the ISO 13485:2016 quality management system standard. This is a significant development because the FDA recently adopted this standard into its updated Quality Management System Regulation, making INBS's existing certification and FDA-registered facility status directly aligned with the new U.S. regulatory framework. This alignment provides crucial structural support for the company's ongoing efforts to secure FDA clearance for its non-invasive fingerprint sweat drug screening system. The market reacted very positively, with INBS shares surging, indicating that investors view this as a strong step towards commercialization and broader market access in the U.S. The short-term implication is a positive sentiment boost and increased investor confidence, while the long-term opportunity lies in successful FDA clearance opening up a substantial new market for their technology.